For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>Nimodipine(Nimotop) is a dihydropyridine derivative and an analogue of the calcium channel blocker nifedipine, with antihypertensive activity.Nimodipine decreases intracellular free Ca2+,Beclin-1 and autophagy.<br>Target: Calcium Channel<br>Nimodipine is main use is in the prevention of cerebral vasospasm and resultant ischemia, a complication of subarachnoid hemorrhage (a form of cerebral bleed), specifically from ruptured intracranial berry aneurysms irrespective of the patient/’s post-ictus neurological condition. Its administration begins within 4 days of a subarachnoid hemorrhage and is continued for three weeks. If blood pressure drops by over 5%, dosage is adjusted. There is still controversy regarding the use of intravenous nimodipine on a routine basis [1, 2].<br></p>
| Catalog Number | I004487 |
| CAS Number | 66085-59-4 |
| Synonyms | 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| Molecular Formula | C21H26N2O7 |
| Purity | ≥95% |
| Target | Autophagy |
| Solubility | DMSO 85 mg/mL; Water <1 mg/mL |
| Storage | 3 years -20C powder |
| InChIKey | UIAGMCDKSXEBJQ-UHFFFAOYSA-N |
| Reference | </br>1:Methodological assessment of the reduction of the content of impurities in nimodipine emulsion via the use of 21 amino acid protection. Xie Y, Zhuang Z, Zhang S, Xia Z, Chen, Fan K, Ren J, Lin C, Chen Y, Yang F.Int J Nanomedicine. 2017 Apr 27;12:3407-3419. doi: 10.2147/IJN.S130348. eCollection 2017. PMID: 28490879 Free PMC Article</br>2:Effects of nimodipine on postoperative delirium in elderly under general anesthesia: A prospective, randomized, controlled clinical trial. Li YN, Zhang Q, Yin CP, Guo YY, Huo SP, Wang L, Wang QJ.Medicine (Baltimore). 2017 May;96(19):e6849. doi: 10.1097/MD.0000000000006849. PMID: 28489775 Free PMC Article</br>3:Nimodipine but Not Nifedipine Promotes Expression of Fatty Acid 2-Hydroxylase in a Surgical Stress Model Based on Neuro2a Cells. Herzfeld E, Speh L, Strauss C, Scheller C.Int J Mol Sci. 2017 May 3;18(5). pii: E964. doi: 10.3390/ijms18050964. PMID: 28467360 Free Article</br>4:Comment: The Effects of 14 Versus 21 Days of Nimodipine Therapy on Neurological Outcomes in Aneurysmal Subarachnoid Hemorrhage Patients. Harbin M, Turgeon R.Ann Pharmacother. 2017 Apr 1:1060028017705394. doi: 10.1177/1060028017705394. [Epub ahead of print] No abstract available. PMID: 28413883 </br>5:Is intra arterial nimodipine really beneficial in vasospasm following aneurysmal subarachnoid hemorrhage? Kumar A, Phalak M.Br J Neurosurg. 2017 Apr 11:1. doi: 10.1080/02688697.2017.1297381. [Epub ahead of print] No abstract available. PMID: 28397570 </br>6:Nimodipine fosters remyelination in a mouse model of multiple sclerosis and induces microglia-specific apoptosis. Schampel A, Volovitch O, Koeniger T, Scholz CJ, Jörg S, Linker RA, Wischmeyer E, Wunsch M, Hell JW, Ergün S, Kuerten S.Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):E3295-E3304. doi: 10.1073/pnas.1620052114. Epub 2017 Apr 5. PMID: 28381594 </br>7:Systemic and Cerebral Concentration of Nimodipine During Established and Experimental Vasospasm Treatment. Albanna W, Weiss M, Conzen C, Clusmann H, Schneider T, Reinsch M, Müller M, Wiesmann M, Höllig A, Schubert GA.World Neurosurg. 2017 Mar 23. pii: S1878-8750(17)30385-6. doi: 10.1016/j.wneu.2017.03.062. [Epub ahead of print] PMID: 28344178 </br>8:Editorial: Nimodipine treatment. Carter BS.J Neurosurg. 2017 Feb 24:1. doi: 10.3171/2016.11.JNS162189. [Epub ahead of print] No abstract available. PMID: 28298030 </br>9:Prophylactic nimodipine treatment and improvement in hearing outcome after vestibular schwannoma surgery: a combined analysis of a randomized, multicenter, Phase III trial and its pilot study. Scheller C, Wienke A, Tatagiba M, Gharabaghi A, Ramina KF, Ganslandt O, Bischoff B, Zenk J, Engelhorn T, Matthies C, Westermaier T, Antoniadis G, Pedro MT, Rohde V, von Eckardstein K, Kretschmer T, Kornhuber M, Steighardt J, Richter M, Barker FG 2nd, Strauss C.J Neurosurg. 2017 Feb 24:1-8. doi: 10.3171/2016.8.JNS16626. [Epub ahead of print] PMID: 28298021 </br>10:Response by Hänggi and Macdonald to Letter Regarding Article, /Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])/. Hänggi D, Macdonald RL.Stroke. 2017 Apr;48(4):e114. doi: 10.1161/STROKEAHA.117.016603. Epub 2017 Mar 10. No abstract available. PMID: 28283608 |
